Announcing Schrödinger Software Release 2016-3
We are pleased to announce Schrödinger software release 2016-3.
In this release, you'll get a chance to beta-test Maestro 11 and provide feedback. This quarterly release also includes usability improvements and performance enhancements across all of our software. Click here to learn more about Maestro 11 beta and to view the list of major new features or click here to download the suites.
Announcing Schrödinger Software Release 2016-2
We are pleased to announce Schrödinger software release 2016-2.
In this release, you'll get a chance to beta-test Maestro 11 and provide feedback. This quarterly release also includes usability improvements and performance enhancements across all of our software.
Schrödinger Announces Co-Founder’s Election to the National Academy of Sciences
NEW YORK, NY (May 3, 2016) – Schrödinger, Inc. announced today that its co-founder, Columbia University Professor Richard A. Friesner, has been elected to be a member of the National Academy of Sciences (NAS). The NAS is a private, non-profit society of distinguished scholars, charged with providing independent, objective advice to the nation on matters related to science and technology. Scientists are elected by their peers to the NAS in recognition of their distinguished and continuing achievements in original research; membership is a widely accepted mark of excellence in science and is considered one of the highest honors that a scientist can receive.
In addition to co-founding Schrödinger, Professor Friesner also chairs Schrödinger’s Scientific Advisory Board, as well as serving on the company’s Board of Directors. “We want to congratulate Rich on this tremendous achievement,” says Dr. Ramy Farid, Schrödinger’s President, “Rich’s strong commitment to science is in Schrödinger’s very DNA – it informs the company’s vision and drives us all to to make breakthroughs that can have a measurable impact on improving people’s lives.” Dr. Farid adds, “It’s been exhilarating to work with a scientist of Rich’s caliber, and we look forward to many more years of productive collaboration.”
Schrödinger congratulates its collaboration partner, Nimbus Therapeutics, on the acquisition by Gilead of Nimbus's ACC program for up to $1.2 billion
Gilead Sciences, Inc. (NASDAQ:GILD) and Nimbus Therapeutics, LLC, announced that the companies have signed a definitive agreement under which Gilead will acquire Nimbus Therapeutics’ Acetyl-CoA Carboxylase (ACC) inhibitor program for up to $1.2 billion. Schrödinger is a co-founder and equity holder of Nimbus and provided the computational platform and support for the ACC program. For more information, please read the press release.
Announcing Schrödinger Software Release 2016-1
We are pleased to announce Schrödinger software release 2016-1. This quarterly release includes usability improvements and performance enhancements across all of our software. Click here to view the list of major new features or click here to download the suites.
Schrödinger Announces Research Collaboration with Pfizer Inc.
NEW YORK, NY (Jan 11, 2016) – Schrödinger, Inc. announced today that it has entered into a research collaboration agreement with Pfizer Inc. (NYSE: PFE), in which the two companies will work together to develop a computational model for predicting key properties relevant to biotherapeutic candidates.
In this collaboration, each company will perform tasks in an attempt to develop a novel model for predictions of properties. Pfizer will generate and provide experimental data against which the computational model is to be developed by the Schrödinger team, while teams from both companies will work together to determine future systems of interest to which to apply, test, and further refine the developing technology.
“Schrödinger has made key scientific breakthroughs in recent years in the areas of protein and ligand structure determination and potency prediction that have made a significant impact on drug discovery,” said Dr. Ramy Farid, Schrödinger’s President and Board Member. “We are thrilled to work together on developing technology that could potentially be applied to pharmaceutical research.”
Shi-Yi Liu, SVP Marketing